CRISPR Revenue Plunges 90% Amid Vertex Collaboration Shift
Ticker: CRSP · Form: 10-Q · Filed: Aug 4, 2025 · CIK: 1674416
Sentiment: bearish
Topics: Biotechnology, Gene Editing, CRISPR, Revenue Decline, Collaboration Risk, Biopharma, 10-Q Analysis
Related Tickers: CRSP, VRTX, EDIT, NTLA
TL;DR
**CRSP's revenue cratered 90% this quarter; time to re-evaluate their pipeline bets.**
AI Summary
CRISPR Therapeutics AG reported collaboration revenue of $1.0 million for the three months ended June 30, 2025, a significant decrease from $10.0 million in the same period of 2024. For the six months ended June 30, 2025, collaboration revenue was $2.0 million, down from $20.0 million in the prior year. The company's net income or loss was not explicitly detailed, but the substantial drop in revenue from its collaboration with Vertex Pharmaceuticals Incorporated indicates a challenging financial quarter. Key business changes include the acquisition of Sirius Therapeutics on May 19, 2025, which is expected to expand its therapeutic pipeline. Risks include the reliance on collaboration agreements, as evidenced by the revenue decline from Vertex, and the inherent uncertainties of clinical development. The strategic outlook focuses on advancing its pipeline and leveraging the Sirius acquisition, but the immediate financial performance shows a contraction in its primary revenue stream.
Why It Matters
CRISPR Therapeutics' 90% drop in collaboration revenue for Q2 2025 signals a critical juncture for investors, highlighting the volatility of biotech partnerships. This revenue decline, primarily from Vertex Pharmaceuticals, could impact the company's ability to fund its ambitious pipeline and maintain its competitive edge against other gene-editing firms like Editas Medicine and Intellia Therapeutics. Employees might face increased pressure to deliver on new drug candidates, while customers and the broader market will watch closely for updates on pipeline progress and new strategic alliances to offset this revenue gap. The acquisition of Sirius Therapeutics is a strategic move, but its impact on financial stability remains to be seen.
Risk Assessment
Risk Level: high — The risk level is high due to the dramatic 90% decrease in collaboration revenue from $10.0 million in Q2 2024 to $1.0 million in Q2 2025. This significant decline, primarily from Vertex Pharmaceuticals, indicates a high dependency on a single collaboration and a substantial reduction in a key funding source for research and development.
Analyst Insight
Investors should closely monitor CRISPR Therapeutics' upcoming pipeline milestones and any new collaboration announcements. Given the sharp revenue decline, consider reducing exposure or waiting for clearer signs of new revenue streams or significant clinical trial success before increasing investment.
Financial Highlights
- revenue
- $1.0M
- revenue Growth
- -90.0%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Collaboration Revenue | $1.0M | -90.0% |
Key Numbers
- $1.0M — Collaboration Revenue (Q2 2025) (90% decrease from $10.0M in Q2 2024)
- $2.0M — Collaboration Revenue (YTD Q2 2025) (90% decrease from $20.0M in YTD Q2 2024)
- 90% — Revenue Decrease (Percentage drop in collaboration revenue from Q2 2024 to Q2 2025)
- 2025-05-19 — Sirius Therapeutics Acquisition Date (Key strategic business change)
Key Players & Entities
- CRISPR Therapeutics AG (company) — filer of the 10-Q
- Vertex Pharmaceuticals Incorporated (company) — primary collaboration partner
- Sirius Therapeutics (company) — acquired by CRISPR Therapeutics on May 19, 2025
- Jefferies LLC (company) — sales agent for 2021 At-Market Offering
- $1.0 million (dollar_amount) — collaboration revenue for Q2 2025
- $10.0 million (dollar_amount) — collaboration revenue for Q2 2024
- $2.0 million (dollar_amount) — collaboration revenue for six months ended June 30, 2025
- $20.0 million (dollar_amount) — collaboration revenue for six months ended June 30, 2024
FAQ
What was CRISPR Therapeutics' collaboration revenue for Q2 2025?
CRISPR Therapeutics AG reported collaboration revenue of $1.0 million for the three months ended June 30, 2025, a substantial decrease from $10.0 million in the same period of 2024.
How did CRISPR Therapeutics' year-to-date revenue compare to the previous year?
For the six months ended June 30, 2025, CRISPR Therapeutics' collaboration revenue was $2.0 million, which is a 90% decrease compared to $20.0 million for the six months ended June 30, 2024.
What significant business change did CRISPR Therapeutics make in Q2 2025?
CRISPR Therapeutics acquired Sirius Therapeutics on May 19, 2025, a strategic move aimed at expanding its therapeutic pipeline and capabilities.
What is the primary risk highlighted by CRISPR Therapeutics' Q2 2025 filing?
The primary risk is the company's high reliance on collaboration agreements, as evidenced by the 90% decline in collaboration revenue from Vertex Pharmaceuticals, indicating potential instability in its primary funding source.
How does the revenue decline impact CRISPR Therapeutics' investors?
The significant revenue decline suggests increased financial pressure and potential delays in pipeline development, which could negatively impact investor confidence and stock performance, requiring careful monitoring of future strategic moves.
Who is CRISPR Therapeutics' main collaboration partner mentioned in the filing?
Vertex Pharmaceuticals Incorporated and its certain subsidiaries are CRISPR Therapeutics' main collaboration partner, responsible for the majority of the collaboration revenue reported.
What was the revenue from Vertex Pharmaceuticals for CRISPR Therapeutics in Q2 2025?
While not explicitly broken out as 'Vertex revenue', the collaboration revenue, primarily from Vertex Pharmaceuticals, was $1.0 million for the three months ended June 30, 2025.
What is the fiscal year end for CRISPR Therapeutics AG?
CRISPR Therapeutics AG's fiscal year ends on December 31st.
Where is CRISPR Therapeutics AG incorporated?
CRISPR Therapeutics AG is incorporated in V8 (Switzerland).
What is the significance of the 2021 At-Market Offering for CRISPR Therapeutics?
The 2021 At-Market Offering, with Jefferies LLC as the sales agent, allowed CRISPR Therapeutics to raise capital through the sale of common shares, providing a mechanism for financing its operations and research.
Risk Factors
- Dependence on Collaboration Revenue [high — financial]: The company's financial performance is heavily reliant on collaboration agreements. The substantial 90% decrease in collaboration revenue from $10.0M in Q2 2024 to $1.0M in Q2 2025, largely from the Vertex Pharmaceuticals collaboration, highlights the financial risk associated with such partnerships.
- Clinical Development Uncertainties [high — operational]: As a biotechnology company, CRISPR Therapeutics faces inherent uncertainties in the clinical development of its product candidates. Delays, failures in clinical trials, or regulatory hurdles can significantly impact the company's pipeline and future revenue streams.
- Integration of Sirius Therapeutics Acquisition [medium — operational]: The recent acquisition of Sirius Therapeutics on May 19, 2025, while intended to expand the pipeline, introduces operational risks related to integration. Successful assimilation of the acquired assets, personnel, and technologies is crucial for realizing the expected benefits.
Industry Context
The biotechnology sector, particularly gene editing, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like CRISPR Therapeutics operate in a competitive landscape with a focus on innovation and strategic partnerships to advance novel therapies.
Regulatory Implications
CRISPR Therapeutics' gene-editing technologies are subject to stringent regulatory review by bodies like the FDA. Any delays or setbacks in clinical trials or regulatory approvals for its product candidates pose a significant risk to the company's future commercialization efforts.
What Investors Should Do
- Monitor Vertex Collaboration Performance
- Assess Sirius Therapeutics Integration Progress
- Evaluate Cash Burn Rate and Funding Needs
Key Dates
- 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing significant revenue decline.
- 2025-05-19: Acquisition of Sirius Therapeutics — Strategic move to expand the company's therapeutic pipeline, but introduces integration risks.
- 2024-04-01: Start of Second Quarter 2024 — Comparison period for Q2 2025 revenue, highlighting a 90% decrease.
Glossary
- Collaboration Revenue
- Revenue generated from agreements with other companies where CRISPR Therapeutics partners on the development or commercialization of its technologies or products. (A key revenue stream for CRISPR Therapeutics, as evidenced by the significant decline reported in this filing.)
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document provides the detailed financial information and business updates for CRISPR Therapeutics for the specified quarter.)
- Pipeline
- The portfolio of drug candidates or therapeutic products that a biotechnology or pharmaceutical company is developing. (The company's strategic focus is on advancing its pipeline, and the Sirius acquisition aims to enhance it.)
Year-Over-Year Comparison
This 10-Q filing reveals a stark contrast to the previous year, with collaboration revenue plummeting by 90% from $10.0M in Q2 2024 to $1.0M in Q2 2025. This significant revenue contraction from its primary revenue stream indicates a challenging financial period. While specific net income figures are not detailed here, the revenue decline suggests a potential widening of losses. No new major risks were explicitly introduced, but the existing risks related to collaboration dependence and clinical development are amplified by the current financial performance.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 4, 2025 regarding CRISPR Therapeutics AG (CRSP).